01 Company overview
Identity and registration
- Official name
- NOVARTIS PHARMACEUTICALS UK LIMITED
- Company number
- 00119006
- Company type
- Private Limited Company
- Status
- Active
- Country of origin
- United Kingdom
- Dissolution date
- Not supplied
A registered office is not necessarily a trading location. The address is reproduced from the Companies House bulk record and should be interpreted in that legal context.
02 Filing dates
Accounts and statements
Last accounts made up to
31 December 2024Next accounts due
30 September 2026Last statement made up to
1 April 2026Next statement due
15 April 2027BritDB does not infer overdue status when the source does not state it.
03 Workforce reporting
Gender pay gap
- Median bonus gap
- 29.3%
- Mean bonus gap
- 31.6%
- Women receiving bonus
- 87.3%
- Men receiving bonus
- 87.1%
- Women in top quartile
- 48.9%
- Women in lower quartile
- 73.4%
Earlier reporting years (8)
- 500 to 99910.6% median hourly gap
- 500 to 99912.2% median hourly gap
- 500 to 99912.1% median hourly gap
- 500 to 9999.0% median hourly gap
- 500 to 9997.9% median hourly gap
- 500 to 9999.7% median hourly gap
- 500 to 9998.4% median hourly gap
- 500 to 9998.6% median hourly gap
Positive gaps mean men were paid more; negative gaps mean women were paid more. These figures are employer-reported and describe the workforce distribution, not equal pay for the same job. The company link uses the exact Companies House number supplied by the service.
04 Supplier payments
Payment practices and performance
- Reporting period
- 1 January 2026 – 30 June 2026
- Filed
- 15 July 2026
- Shortest standard term
- 60 days
- Longest standard term
- Not supplied
- E-invoicing offered
- Yes
- Supply-chain finance
- Not offered
- Payment codes
- No
- Construction retentions
- No retention clauses reported
Reported terms and dispute process
- Standard payment terms
Standard payment terms are 60 days following the invoice receipt at Novartis. Depending on the commercial situation, variations to these standard terms might be negotiated on some occasions.
- Dispute resolution process
First point of contact for disputes or concerns is the Procure-to-Payment team within the Novartis Global Services Centre, for which all suppliers have contact details of. In addition to that, new suppliers receive an on-boarding pack, which includes information on issue raising and related points of contact. When an invoice dispute is received, it should be resolved at point of contact with the Procure-to-Payment team. If this is not possible, the query will be escalated to the Business contact and relevant senior Finance contact or P2P Business Partner. Timelines of escalation vary, depending on the nature of the query. When resolved, the invoice will be available for payment on the next standard payment run.
Earlier payment reports (11 shown)
- 60.0 average days to pay9.0% outside terms
- 55.0 average days to pay26.0% outside terms
- 58.0 average days to pay14.0% outside terms
- 69.0 average days to pay13.0% outside terms
- 63.0 average days to pay16.0% outside terms
- 62.0 average days to pay17.0% outside terms
- 60.0 average days to pay15.0% outside terms
- 58.0 average days to pay16.0% outside terms
- 52.0 average days to pay12.0% outside terms
- 55.0 average days to pay21.0% outside terms
- 53.0 average days to pay22.0% outside terms
This is a company-submitted statutory disclosure, not a credit rating. BritDB preserves the reporting period and links the report only through the Companies House number supplied by the official service. Percentages describe payments made during that period and may change in later reports.
05 Supply-chain transparency
Modern slavery statement
- Organisation
- NOVARTIS PHARMACEUTICALS UK LIMITED
- Group submission
- Yes
- Statement period
- 1 January 2025 – 31 December 2025
- Approved
- 4 February 2026
- Sectors
- Healthcare and pharmaceuticals
Organisation structure
Covered in the statement
Policies
Covered in the statement
Risk assessment
Covered in the statement
Due diligence
Covered in the statement
Training
Covered in the statement
Goals and KPIs
Covered in the statement
A registry entry records what the organisation declared in its statement. It is not an independent audit. Group statements can cover several companies; BritDB preserves each exact source-supplied company-number link and excludes approver names and email addresses.
06 Data protection
ICO fee-payer registration
Novartis Pharmaceuticals UK Limited
Registration Z6641953
- Registered from
- 11 April 2002
- Current end date
- 10 April 2027
This is a candidate association, not an official Companies House link. The ICO file supplies no company number. The organisation name and postcode uniquely matched this company in the current snapshot. BritDB excludes all DPO contact fields and does not publish unmatched personal entries.
07 Public procurement
Contracts Finder awards
NHS Framework, North of England, Branded Medicines-Tranche A and Annual Tranche
NHS England · ocds-b5fd17-711f74f7-430c-4b80-a5e0-b3ce69f928b9
- Award value
- £1
- Contract period
- 1 March 2021 – 28 February 2023
- Procedure
- Open procedure (above threshold)
NHS Framework for the Midlands and East, Branded Medicines - Tranche B
NHS England · ocds-b5fd17-a3813112-7a5b-461b-9e42-ccdb117c93ef
- Award value
- £228,156,862
- Contract period
- 1 March 2021 – 28 February 2023
- Procedure
- Open procedure (above threshold)
NHS Framework for the NHS London Region, Branded Medicines - Tranche A
NHS England · ocds-b5fd17-20ae12c6-3ba8-40bb-b423-51a2c2de6a67
- Award value
- £191,062,951
- Contract period
- 1 September 2020 – 31 August 2022
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement - North of England - Tranche B
NHS England · ocds-b5fd17-2774d91d-05e7-400d-a217-4a5ca9db01ef
- Award value
- £205,535,556
- Contract period
- 1 March 2020 – 28 February 2022
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement for Branded medicines - London - Tranche B - Contracts Finder Opportunity
NHS England · ocds-b5fd17-aaa2bd9e-0fdb-4884-8fca-b0d29a6ed15a
- Award value
- £251,930,337
- Contract period
- 1 September 2019 – 31 August 2020
- Procedure
- Open procedure (above threshold)
NHS Framework Agreement for Branded Medicines - National
NHS England · ocds-b5fd17-67d93048-4af9-4a0e-b313-bc852f01fca7
- Award value
- £1,351,341,890
- Contract period
- 1 May 2019 – 30 April 2021
- Procedure
- Open procedure (above threshold)
NHS Framework agreement for Branded Medicines - North of England - Tranche A
NHS England · ocds-b5fd17-2e43909f-31cc-4421-9f28-e9e4f18738ed
- Award value
- £204,551,038
- Contract period
- 1 March 2019 – 28 February 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-6c7a4e2c-58d3-4c41-8f77-dc419f83871c
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-9878d09a-d11a-4940-a851-2b2b759217f2
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-679e36df-b147-44d9-b0c1-53e4b91250c8
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-8aaddf75-dd22-4754-b241-885b44819814
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Procedure
- Open procedure (above threshold)
NHS England Framework Agreement: South of England (Tranche B)
NHS England · ocds-b5fd17-3dac71e6-cde5-406b-abc4-e91389859bf5
- Award value
- £501,400,000
- Contract period
- 1 September 2018 – 31 August 2020
- Procedure
- Open procedure (above threshold)
The supplier link is exact, but the award remains buyer-published procurement data. BritDB requires the GB-COH identifier supplied in the Contracts Finder OCDS release and does not infer suppliers from similar names.
08 Ownership and control
People with significant control
Novartis Uk Limited
- Owns 75% or more of shares
- Controls 75% or more of voting rights
- Can appoint or remove directors
- Notified
- 6 April 2016
PSC records are company-filed public-register information. When the exact same displayed individual name occurs at multiple companies, BritDB offers a non-indexed cross-reference page. It is a name match only, not proof that the records describe the same person. Service addresses and partial dates of birth are deliberately omitted.
09 Charity register
Charity Commission links
No exact company-number link in this snapshot
The Charity Commission extract did not explicitly associate this Companies House number with a charity. BritDB does not use a name-only match to fill the gap.
This company-level check covers the Charity Commission for England and Wales. Links are accepted only when the official extract supplies this exact company registration number. Scottish charities now have separate OSCR profiles, but OSCR’s bulk fields do not provide a Companies House number, so BritDB does not infer a company link.
10 Northern Ireland charity register
CCNI exact company links
No unambiguous company-number link found
The CCNI source number did not resolve uniquely to this Companies House record. BritDB did not use a name or address match.
CCNI publishes company numbers without a jurisdiction prefix. BritDB links only when the plausible padded UK and NI candidates resolve to exactly one Companies House company.
11 Sanctions screening
UK Sanctions List
No exact business-registration-number link found
The imported UK Sanctions List did not supply this Companies House number as a UK-linked business identifier. BritDB did not attempt a name-only match.
No exact link is not sanctions clearance. UK restrictions can apply through ownership or control even where an entity is not separately named. Always use the current official list and obtain appropriate advice for a legally significant decision.
12 Public procurement
Find a Tender links
REVOLADE (ELTROMBOPAG) TABLETS, 28 tablet
Belfast Health & Social Care Trust · updated 7 July 2026
- Tender value
- Not supplied
- Awards
- 1
Generic, Branded Generic & Proprietary Medicinal Products - Group 18
Regional Business Services Organisation, Procurement and Logistics Service · updated 3 July 2026
- Tender value
- £1,800,000,000
- Awards
- 214
Utathera 7400MBq/20.5-25ml solution
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · updated 30 June 2026
- Tender value
- Not supplied
- Awards
- 1
solution for infusion vial
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · updated 29 May 2026
- Tender value
- Not supplied
- Awards
- 1
TRAMETINIB 2MG TABLETS, 30 tablet, pack
Belfast Health & Social Care Trust · updated 21 May 2026
- Tender value
- Not supplied
- Awards
- 1
IPTACOPAN HYDROCHLORIDE MONOHYDRATE 200MG CAPSULES, 56 capsules, pack
Belfast Health & Social Care Trust · updated 20 April 2026
- Tender value
- Not supplied
- Awards
- 1
NHS National Framework Agreement for Omalizumab
NHS England · updated 30 December 2025
- Tender value
- £85,785,000
- Awards
- 2
SECUKINUMAB 150 mg in 1mL Injection, SECUKINUMAB 300 mg in 2mL Solution for Injection
Western Health & Social Care Trust · updated 8 December 2025
- Tender value
- Not supplied
- Awards
- 1
PRRT (Peptide Receptor Radionuclide Therapy)
Belfast Health & Social Care Trust · updated 2 December 2025
- Tender value
- Not supplied
- Awards
- 1
Asciminib Tablets, 60 tablet pack, all strengths
Belfast Health & Social Care Trust · updated 13 October 2025
- Tender value
- Not supplied
- Awards
- 1
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England · updated 6 October 2025
- Tender value
- £1,520,432,295
- Awards
- 3
NHS National Framework for Transition products (Axitinib and Eltrombopag)
NHS England · updated 4 September 2025
- Tender value
- £80,909,200
- Awards
- 1
MIDOSTAURIN 25MG CAPSULES
Northern Health And Social Care Trust · updated 3 September 2025
- Tender value
- Not supplied
- Awards
- 1
ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL
Northern Health And Social Care Trust · updated 3 September 2025
- Tender value
- Not supplied
- Awards
- 1
Canakinumab
Northern Health And Social Care Trust · updated 3 September 2025
- Tender value
- Not supplied
- Awards
- 1
NHS National Framework for Transition products (Nilotinib and Ticagrelor)
NHS England · updated 20 August 2025
- Tender value
- £29,042,000
- Awards
- 2
MIDOSTAURIN 25MG CAPSULES, 56 capsules
Belfast Health & Social Care Trust · updated 1 July 2025
- Tender value
- Not supplied
- Awards
- 1
SECUKINUMAB 300 mg Pre-filled Injection 1 Pen Pack
BELFAST HEALTH AND SOCIAL CARE TRUST · updated 10 February 2025
- Tender value
- Not supplied
- Awards
- 1
RIBOCICLIB 200 mg Tablets 63 Tablet Pack
BELFAST HEALTH AND SOCIAL CARE TRUST · updated 5 November 2024
- Tender value
- Not supplied
- Awards
- 1
Contract for ASCIMINIB 40mg tablets
Northern Health and Social Care Trust · updated 28 October 2024
- Tender value
- Not supplied
- Awards
- 1
Showing the first 20 of 29 linked procurement processes.
These links use only the GB-COH identifier supplied in the procurement record. A company may have other public-sector work that is absent, older, below publication thresholds or published without a Companies House identifier.
13 Environmental register
Environment Agency waste registrations
No exact company-number registration linked
The licensed Environment Agency subset did not contain this exact Companies House number. BritDB did not attempt a name-only match.
This is a privacy-reduced, exact-company subset. The full official register also includes sole traders and applicants without a matching Companies House number. Check the current Environment Agency register before relying on registration status.
14 Nature of business
Standard Industrial Classification
Manufacture of basic pharmaceutical products
15 Connected public record
Checks beyond the company register
Charity Commission
0 exact company-number links.
Northern Ireland charities
0 unambiguous company-number links.
Public contracts
29 procurement processes linked by exact GB-COH identifier.
Waste register
0 exact company-number registrations.
Corporate notices
The Gazette is not yet connected.
UK Sanctions List
No exact business-registration-number link in this report.
A checked source with no exact link is not a clean bill of health. Unchecked sources remain unknown, while sanctions may also apply through ownership or control of a listed person or entity.
16 Record timeline
Dates in the bulk record
- Confirmation statement
Latest confirmation statement made up to this date
- Accounts
Latest accounts made up to this date
- Incorporation
Company incorporated
17 Provenance
Sources for this profile
Identity, address, status, dates, SIC, previous names and mortgage totals.
Annual employer reports linked by the exact source-supplied Companies House number.
Statutory supplier-payment reports linked by the exact source-supplied Companies House number.
Annual statement summaries linked by exact source company number.
Privacy-reduced candidate associations based on a unique exact name-and-postcode match.
Historic awards linked by exact source-supplied GB-COH company identifier.
Current and ceased significant-control records joined by exact company number.
Daily England and Wales extract matched only by the official company registration number.
Daily CCNI export with company links only where the source number resolves unambiguously.
Complete FCDO list checked by exact UK-linked business registration number.
Procurement parties checked only through exact GB-COH identifiers.
Licensed subset linked only by exact Companies House number.
Financial regulation and licences.
Companies House, Charity Commission, OSCR and UK Sanctions List information is public-register data. BritDB reproduces and organises it with source-specific limits; official external links are kept on the dedicated source pages.